PETS · Petmed Express Inc
$1.20
+0.05 (+3.91%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 13, 2026
The latest filing states the doubt was alleviated.
“During the three months ended June 30, 2026, management's assessment identified certain conditions and events that, when considered in the aggregate, raised substantial doubt about the Company's ability to continue as a going concern. ... Management determined that these plans are probable of being effectively implemented and are probable of mitigating the conditions that raised substantial doubt. As of the issuance of these financials, management has concluded that substantial doubt about the Company's ability to continue as a going concern for the next twelve months is alleviated by these plans.”View the 10-Q filed Aug 13, 2026
Market Cap
$24.93M
Shares
21.68M
Volume · Oct 20
44.45K
Avg daily vol (3M)
113.95K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.15
Open$1.16
Day$1.15–1.20
52W close$1.15–3.90
Avg vol 30d133K
Short int692K · 3.2% float · 4.2d
Short vol39%
Last earningsAug 13, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Dec 2, 2026
Est · unconfirmed
· in 6 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$168.86M
Trailing 12 months
Net income (TTM)
−$29.28M
Trailing 12 months
Revenue growth YoY
-19.9%
Year over year
Operating margin
-18.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$13.08M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.5%
Year over year · more shares
Price change (1Y)
-54.2%
Trailing year
Short interest
3.2%
Latest settlement · 4.2 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−48%
below
Price vs 50-day avg
−28%
below
RSI (14)
15
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−49%
trailing
YTD return
−64%
this year
Relative strength
−57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
3 of 49 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.19% of float · ▲ +21.5% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
49 holders — near 3-yr low, contrarian setup
Squeeze score
53
elevated · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
18%
contracting
EPS growth
−813%
Y/Y
Free cash flow
$-33.0M
Buyback
$28.7M
remaining
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−48%
Bearish
Price vs 50-day avg
−28%
Bearish
RSI (14)
15
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
3 of 49 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.19% of float · ▲ +21.5% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
49 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $4
vs 200-day avg -48%
vs 50-day avg -28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$3.45M | the three months ended June 30, 2026 filing | — |
|
|
|||
| Customer acquisition costs | $60 | three months ended June 30, 2026 filing | — |
| Membership fees earned under the partner programs | $1.2M | the three months ended June 30, 2026 filing | — |
| Recurring net sales as a percentage of total gross sales | 61.5% | the most recent quarter ended June 30, 2026 filing | — |
| Average order value | $98 | fiscal 2026 filing | +1.0% |
|
|
|||
| declining net sales by approximately | 21.1% | the year ended March 31, 2026 filing | — |
| Inventory spend concentrated among ten primary suppliers | 88% | fiscal 2026 filing | — |
| New customers attracted | 266,000 | fiscal 2026 filing | -24.2% |
|
|
|||
| New order sales | 24.73M | Year Ended March 31, 2026 filing | — |
| Reorder sales | 147.79M | Year Ended March 31, 2026 filing | — |
| Share of total purchases from suppliers that each accounted for 2% or more of total purchase vol | 89% | fiscal 2026 filing | +9.9% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Pharmaceutical Retailers — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PETS
this stock
Petmed Express Inc
|
$24.93M | -64.1% | +9.9% | — | 3.2% |
|
RTEZ
REST EZ Inc.
|
$4.20B | — | -100.0% | — | 0.0% |
|
HITI
High Tide Inc.
|
$233.55M | -1.1% | — | — | 0.8% |
|
BHIC
BioScience Health Innovations, Inc.
|
$79.68M | — | +208.3% | — | 0.0% |
|
SHFH
Scientist Home Future Health Ltd
|
$40.32M | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PETS | -8.7% | -28.1% | -48.9% | -16.7% | -64.1% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -7.2% | -27.2% | -56.6% | -17.2% | -76.5% |
Capital returns
Buyback program
· as of Dec 31, 2023
Authorized
$110.00M
Spent (derived)
$81.30M
Remaining
$28.70M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.